FDA Approves Osimertinib/Chemo in EGFR-Mutated NSCLC

News
Article

Data from the phase 3 FLAURA 2 trial support the FDA approval of osimertinib plus chemotherapy for treating patients with EGFR-mutated non–small cell lung cancer.

Supporting data for the FDA approval of osimertinib in EGFR-mutated non–small cell lung cancer came from the phase 3 FLAURA 2 trial (NCT04035486).

Supporting data for the FDA approval of osimertinib in EGFR-mutated non–small cell lung cancer came from the phase 3 FLAURA 2 trial (NCT04035486).

The FDA has granted approval to osimertinib (Tagrisso) in combination with platinum-based chemotherapy as a treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R mutations, according to a press release from the agency.1

The regulatory agency approved osimertinib at a recommended dose of 80 mg orally twice a day with or without food until acceptable toxicity or progressive disease.

Supporting data for the approval of osimertinib in this indication came from the phase 3 FLAURA 2 trial (NCT04035486). Data highlighted a median progression-free survival (PFS) of 25.5 months (95% CI, 24.7-not estimable [NE) with osimertinib plus chemotherapy compared with 16.7 months (95% CI, 14.1-21.3) in those who received osimertinib monotherapy (HR, 0.62; 95% CI, 0.49-0.79; P <.0001).

Currently, overall survival data are still immature, but 45% of prespecified deaths were reported, and there was not a detriment observed.

In the open-label FLAURA 2 trial, 557 patients with EGFR-mutated advanced or metastatic NSCLC were randomly assigned 1:1 to receive osimertinib alone or in combination with platinum-containing chemotherapy.

The trial’s primary efficacy end point was PFS per investigator assessment. OS was a key secondary end point.

The most common adverse effects observed in the osimertinib/chemotherapy arm included leukopenia, thrombocytopenia, neutropenia, lymphopenia, and rash.

The FDA previously granted priority review to a supplemental biologics license application for osimertinib as a treatment for those with advanced or metastatic NSCLC harboring EGFR mutations in October 2023.2

References

  1. FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer. News release. FDA. February 16, 2024. Accessed February 16, 2024. https://bit.ly/49AeXjy
  2. Tagrisso plus chemotherapy granted priority review in the US for patients with EGFR-mutated advanced lung cancer. News release. AstraZeneca. October 16, 2023. Accessed February 16, 2024. https://bit.ly/3ZUDUm9
Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Sandip Patel, MD, and Helena Yu, MD, presenting slides
Sandip Patel, MD, and Helena Yu, MD, presenting slides
Sandip Patel, MD, and Helena Yu, MD, presenting slides
Sandip Patel, MD, and Helena Yu, MD, presenting slides
Sandip Patel, MD, and Helena Yu, MD, presenting slides
Sandip Patel, MD, and Helena Yu, MD, presenting slides
Related Content
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC

April 23rd 2024
Article

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

April 18th 2024
Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.

Combatting Stigmatization to Increase Lung Cancer Screening Access

February 12th 2024
Podcast

Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.

The phase 1/2 WU-KONG1 findings support the breakthrough therapy designation for sunvozertinib for those with EGFR-mutated non–small cell lung cancer.

Sunvozertinib Earns FDA Breakthrough Therapy Designation in EGFR+ NSCLC

April 9th 2024
Article

The phase 1/2 WU-KONG1 findings support the breakthrough therapy designation for sunvozertinib for those with EGFR-mutated non–small cell lung cancer.

Data from a phase 3b trial support a supplemental new drug application in China for savolitinib in previously treated non–small cell lung cancer with MET exon 14 alterations.

China Accepts sNDA for Savolitinib in Previously Treated MET Exon 14 NSCLC

April 6th 2024
Article

Data from a phase 3b trial support a supplemental new drug application in China for savolitinib in previously treated non–small cell lung cancer with MET exon 14 alterations.